Comparison 1.
Anti‐leukaemic therapy plus anti‐CD20 versus anti‐leukaemic therapy alone (anti‐leukaemic therapy identical in both groups)
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 OS ‐ overall analysis | 3 | 1421 | Hazard Ratio (Fixed, 95% CI) | 0.78 [0.62, 0.98] |
| 2 OS ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 2.1 first‐line treatment | 1 | 817 | Hazard Ratio (Fixed, 95% CI) | 0.67 [0.48, 0.94] |
| 2.2 previously treated | 2 | 604 | Hazard Ratio (Fixed, 95% CI) | 0.89 [0.65, 1.22] |
| 3 OS ‐ subgrouped by different treatment regimens | 3 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 3.1 FluC‐R versus FluC | 2 | 1369 | Hazard Ratio (Fixed, 95% CI) | 0.74 [0.59, 0.94] |
| 3.2 FluCM‐R versus FluCM | 1 | 52 | Hazard Ratio (Fixed, 95% CI) | 1.28 [0.60, 2.76] |
| 4 PFS ‐ overall analysis | 3 | 1421 | Hazard Ratio (Fixed, 95% CI) | 0.64 [0.55, 0.74] |
| 5 PFS ‐ subgrouped by age | 2 | Hazard Ratio (Random, 95% CI) | Subtotals only | |
| 5.1 < 65 years | 2 | 889 | Hazard Ratio (Random, 95% CI) | 0.53 [0.44, 0.65] |
| 5.2 ≥ 65 years | 1 | 245 | Hazard Ratio (Random, 95% CI) | 0.55 [0.38, 0.80] |
| 5.3 ≥ 65 years to < 70 years | 1 | 142 | Hazard Ratio (Random, 95% CI) | 0.87 [0.56, 1.35] |
| 5.4 ≥ 70 years | 1 | 93 | Hazard Ratio (Random, 95% CI) | 0.99 [0.58, 1.69] |
| 6 PFS ‐ subgrouped by stage | 2 | Hazard Ratio (Random, 95% CI) | Subtotals only | |
| 6.1 Binet A | 2 | 95 | Hazard Ratio (Random, 95% CI) | 0.59 [0.31, 1.10] |
| 6.2 Binet B | 2 | 848 | Hazard Ratio (Random, 95% CI) | 0.56 [0.43, 0.72] |
| 6.3 Binet C | 2 | 423 | Hazard Ratio (Random, 95% CI) | 0.67 [0.52, 0.88] |
| 7 PFS ‐ subgrouped by prognostic factor | 2 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 7.1 del17p | 2 | 93 | Hazard Ratio (Fixed, 95% CI) | 0.59 [0.37, 0.95] |
| 7.2 del 11q | 2 | 705 | Hazard Ratio (Fixed, 95% CI) | 0.38 [0.29, 0.51] |
| 7.3 trisomy 12 | 2 | 143 | Hazard Ratio (Fixed, 95% CI) | 0.60 [0.35, 1.03] |
| 7.4 del13q | 2 | 659 | Hazard Ratio (Fixed, 95% CI) | 0.52 [0.41, 0.66] |
| 8 PFS ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 8.1 first‐line treatment | 1 | 817 | Hazard Ratio (Fixed, 95% CI) | 0.56 [0.46, 0.68] |
| 8.2 previously treated | 2 | 604 | Hazard Ratio (Fixed, 95% CI) | 0.75 [0.61, 0.94] |
| 9 PFS ‐ subgrouped by different treatment regimens | 3 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 9.1 FluC‐R versus FluC | 2 | 1369 | Hazard Ratio (Fixed, 95% CI) | 0.63 [0.55, 0.74] |
| 9.2 FluCM‐R versus FluCM | 1 | 52 | Hazard Ratio (Fixed, 95% CI) | 0.72 [0.39, 1.32] |
| 10 Time to next treatment ‐ overall analysis | 2 | 1369 | Hazard Ratio (Fixed, 95% CI) | 0.61 [0.51, 0.73] |
| 11 Time to next treatment ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 2 | Hazard Ratio (Fixed, 95% CI) | Subtotals only | |
| 11.1 first‐line treatment | 1 | 817 | Hazard Ratio (Fixed, 95% CI) | 0.59 [0.47, 0.74] |
| 11.2 previously treated | 1 | 552 | Hazard Ratio (Fixed, 95% CI) | 0.65 [0.49, 0.86] |
| 12 ORR ‐ overall analysis | 3 | 1421 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [1.09, 1.23] |
| 13 ORR ‐ subgrouped by age | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 13.1 < 65 years | 2 | 889 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.19 [1.10, 1.29] |
| 13.2 ≥ 65 years | 1 | 245 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.12 [1.02, 1.23] |
| 13.3 ≥ 65 years to < 70 years | 1 | 142 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.42 [0.72, 2.81] |
| 13.4 ≥ 70 years | 1 | 93 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.82 [0.80, 4.14] |
| 14 ORR ‐ subgrouped by stage | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 14.1 Binet A | 2 | 95 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.54 [1.10, 2.17] |
| 14.2 Binet B | 2 | 848 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.15 [1.07, 1.24] |
| 14.3 Binet C | 2 | 423 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.21 [1.05, 1.39] |
| 15 ORR ‐ subgrouped by prognostic factor | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 15.1 del17p | 2 | 93 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.09 [1.20, 3.64] |
| 15.2 del11q | 2 | 694 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.14 [0.97, 1.34] |
| 15.3 trisomy 12 | 2 | 130 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.18 [0.94, 1.48] |
| 15.4 del13q | 2 | 533 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.39 [1.22, 1.59] |
| 16 ORR ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 16.1 first‐line treatment | 1 | 817 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.13 [1.06, 1.19] |
| 16.2 previously treated | 2 | 604 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.23 [1.07, 1.43] |
| 17 ORR ‐ subgrouped by different treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 17.1 FluC‐R versus FluC | 2 | 1369 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [1.09, 1.24] |
| 17.2 FluCM‐R versus FluCM | 1 | 52 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.13 [0.74, 1.75] |
| 18 CRR ‐ overall analysis | 3 | 1421 | Risk Ratio (M‐H, Random, 95% CI) | 2.11 [1.72, 2.59] |
| 19 CRR ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 19.1 first‐line treatment | 1 | 817 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.05 [1.65, 2.54] |
| 19.2 previously treated | 2 | 604 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.9 [1.44, 5.84] |
| 20 CRR ‐ subgrouped by different treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 20.1 FluC versus FluC‐R | 2 | 1369 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.14 [1.74, 2.64] |
| 20.2 FluCM versus FluCM‐R | 1 | 52 | Risk Ratio (M‐H, Fixed, 95% CI) | 2.0 [0.40, 9.99] |
| 21 MRD negativity ‐ overall analysis | 2 | 121 | Risk Ratio (M‐H, Random, 95% CI) | 1.43 [0.81, 2.54] |
| 22 MRD negativity ‐ subgrouped by different treatment regimens | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 22.1 FluC versus FluC‐R | 1 | 69 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.38 [0.73, 2.61] |
| 22.2 FluCM versus FluCM‐R | 1 | 52 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.67 [0.44, 6.26] |
| 23 Treatment‐ related mortality ‐ overall analysis | 3 | 1415 | Risk Ratio (M‐H, Random, 95% CI) | 1.19 [0.70, 2.01] |
| 24 Treatment‐ related mortality ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 24.1 first‐line treatment | 1 | 817 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.80 [0.32, 2.01] |
| 24.2 previously treated | 2 | 598 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.46 [0.77, 2.75] |
| 25 Treatment‐ related mortality ‐ subgrouped by different treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 25.1 FluC‐R versus FluC | 2 | 869 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.00 [0.44, 2.28] |
| 25.2 FluCM‐R versus FluCM | 1 | 546 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.35 [0.69, 2.63] |
| 26 SAEs ‐ overall analysis | 2 | 598 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.05 [0.89, 1.23] |
| 27 SAEs ‐ subgrouped by different treatment regimens | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 27.1 FluC versus FluC‐R | 1 | 546 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.05 [0.88, 1.24] |
| 27.2 FluCM versus FluCM‐R | 1 | 52 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.08 [0.64, 1.82] |
| 28 Grade 3/4 AEs ‐ overall analysis | 3 | 1398 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.15 [1.08, 1.23] |
| 29 Grade 3/4 AEs ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 29.1 first‐line treatment | 1 | 800 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.22 [1.11, 1.33] |
| 29.2 previously treated | 2 | 598 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.08 [0.99, 1.18] |
| 30 Grade 3/4 AEs ‐ subgrouped by different treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 30.1 FluC versus FluC‐R | 2 | 1346 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [1.08, 1.24] |
| 30.2 FluCM versus FluCM‐R | 1 | 52 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.04 [0.87, 1.25] |
| 31 Anaemia grade 3/4 ‐ overall analysis | 2 | 1346 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.88 [0.62, 1.24] |
| 32 Anaemia grade 3/4 ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 32.1 first‐line treatment | 1 | 800 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.80 [0.46, 1.38] |
| 32.2 previously treated | 1 | 546 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.94 [0.60, 1.46] |
| 33 Neutropenia grade 3/4 ‐ overall analysis | 3 | 1398 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.28 [1.11, 1.48] |
| 34 Neutropenia grade 3/4 ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 34.1 first‐line treatment | 1 | 800 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.61 [1.27, 2.03] |
| 34.2 previously treated | 2 | 598 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.06 [0.88, 1.28] |
| 35 Neutropenia grade 3/4 ‐ subgrouped by different treatment regimens | 3 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 35.1 FluC versus FluC‐R | 2 | 1346 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.30 [1.12, 1.52] |
| 35.2 FluCM versus FluCM‐R | 1 | 52 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.0 [0.60, 1.65] |
| 36 Thrombocytopenia grade 3/4 ‐ overall analysis | 2 | 1346 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.86 [0.61, 1.19] |
| 37 Thrombocytopenia grade 3/4 ‐ subgrouped by different anti‐CD20 antibody treatment regimens | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
| 37.1 first‐line treatment | 1 | 800 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.67 [0.43, 1.04] |
| 37.2 previously treated | 1 | 546 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.20 [0.72, 2.01] |